Mirum Pharmaceuticals (MIRM) achieves successive clinical successes in rare liver diseases…revenue upgraded to $680 million
Mirum Pharmaceuticals (MIRM) is gaining market attention by successively disclosing significant clinical progress in rare liver disease treatments, while also pursuing performance growth, fundraising, and pipeline expansion strategies to strengthen long-term growth drivers.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 50.1%.